Evidence map›Paper›PMID 39276054›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2024

[Tujia medicine

S Xiang, Z Zhang, L Jiang, D Liu, W Li, Z Bao, R Tian, D Cheng, L Yuan

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. [Molecular mechanism ofNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025
    Article
  2. [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

S Xiang1Hubei Enshi college, Enshi 445000, China.
Z ZhangHubei Provincial Key Laboratory of Occurrence and Intervention of Rheumatic Diseases, Hubei Minzu University, Enshi 445000, China.
L JiangHubei Provincial Key Laboratory of Occurrence and Intervention of Rheumatic Diseases, Hubei Minzu University, Enshi 445000, China.
D LiuHubei Provincial Key Laboratory of Occurrence and Intervention of Rheumatic Diseases, Hubei Minzu University, Enshi 445000, China.
W LiHubei Provincial Key Laboratory of Occurrence and Intervention of Rheumatic Diseases, Hubei Minzu University, Enshi 445000, China.
Z BaoHubei Provincial Key Laboratory of Occurrence and Intervention of Rheumatic Diseases, Hubei Minzu University, Enshi 445000, China.
R TianHubei Provincial Key Laboratory of Occurrence and Intervention of Rheumatic Diseases, Hubei Minzu University, Enshi 445000, China.
D ChengHubei Provincial Key Laboratory of Occurrence and Intervention of Rheumatic Diseases, Hubei Minzu University, Enshi 445000, China.
L YuanHubei Provincial Key Laboratory of Occurrence and Intervention of Rheumatic Diseases, Hubei Minzu University, Enshi 445000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the therapeutic mechanism of Tujia medicine

methodsSixty male SD rats were randomized into normal control group, CIA model group, TGT group, 3 TAAE treatment groups at low, medium and high doses (

resultsTreatment of CIA rat models with TAAE and TGT significantly alleviated paw swelling, lowered AI scores, and reduced knee joint pathology, neoangiogenesis, and serum levels of inflammatory factors. TAAE treatment obviously increased endostatin protein expression, downregulated p-PI3K, p-Akt, MMP1, MMP3, MMP9, VEGF, and HIF-1α proteins, and reduced TNF‑α, IL-6, IL-1β, PI3K, Akt, VEGF, and HIF-1α mRNA levels in the synovial tissues, and these changes were comparable between high-dose TAAE group and TGT group.

conclusionTAAE can improve joint symptoms and inhibit synovial pannus formation in CIA rats by regulating the expressions of HIF-1α, VEGF, endostatin, MMP1, MMP3, and MMP9 via the PI3K/Akt signalling pathway.

Indexed as

Arthritis, ExperimentalHypoxia-Inducible Factor 1, alpha SubunitPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRats, Sprague-DawleySignal TransductionVascular Endothelial Growth Factor AAnimalsDrugs, Chinese HerbalEndostatinsInterleukin-1betaInterleukin-6MaleMatrix Metalloproteinase 1Matrix Metalloproteinase 3Matrix Metalloproteinase 9Drugs, Chinese HerbalEndostatinsHif1a protein, ratHypoxia-Inducible Factor 1, alpha SubunitInterleukin-1betaInterleukin-6Matrix Metalloproteinase 1Matrix Metalloproteinase 3Matrix Metalloproteinase 9MMP1 protein, ratMmp9 protein, ratPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTumor Necrosis Factor-alphaVascular Endothelial Growth Factor Avascular endothelial growth factor A, ratinflammationpannusPI3K/Akt signaling pathwayrheumatoid arthritisToddalia asiatica

Identifiers

PMID39276054
PMCPMC11378040

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.